Pillar 1: Transforming Allergy Care
Accelerating Breakthroughs. Changing Lives
Problem: Allergic disease is one of Australia’s fastest-growing public health challenges. As we work to fully understand why, better prevention, diagnosis, and treatment strategies are urgently needed.
Solution: This Pillar pinpoints critical knowledge and care gaps and co-designs tailored national trials and programs with consumers. The aim? Delivering real-world impact for Australians living with drug, food, insect and respiratory allergic disease.
“Through our work, we want to change the trajectory of allergic disease in Australia so that more people can go to school and work without the risk of a life-threatening reaction.”
- Director of the National Allergy Centre of Excellence and the Centre for Food Allergy Research.
- Group Leader of Population Allergy, Murdoch Children's Research Institute.
- Paediatric Allergist and Vaccinologist, The Royal Children’s Hospital Melbourne.
- Honorary Professorial Fellow, Department of Paediatrics, The University of Melbourne.
Penicillin allergy delabelling
The NACE and the International Network of Antibiotic Allergy Nations (iNAAN) are partnering to scale the network of 47 hospitals to include additional sites for paediatrics, and support further research through the sharing of data with the NACE Allergy BioRepository (ALBI).
Coming soon
ADAPT OIT Program and NACE Evaluation Study
Ten paediatric tertiary hospitals across five states partnered with the NACE to introduce the world’s first standardised, national model of care for treatment of infant peanut allergy. The NACE leads an improvement science evaluation framework to ensure a comprehensive, patient-centred and evidence-based approach.
Optimising the management of Jack Jumper Ant allergy
Australia’s three centres to offer Jack Jumper Ant Venom Immunotherapy (JJA VIT) in Tasmania, South Australia and Victoria have partnered with the NACE to develop the JAVELIN Trial. Starting in spring 2025, it will recruit 150 adults to determine the long-term effectiveness of JJA VIT.
Improving the lives of young Australians with hay fever
Seventeen general practice and allergy clinics from all states and territories have partnered with the NACE to launch the ARISE Trial - a clinical trial improving the management of the country’s most common allergic disease. It is recruiting 14- to 29-year-olds from across Australia.
Advancing anaphylaxis care
The Royal Children’s Hospital, Melbourne has partnered with the NACE to introduce a digital registry to make data-driven advances in the understanding, effectiveness and safety of anaphylaxis management. To date, over 450 children and adolescence, who have presented to ED with anaphylaxis, have had their complete data recorded for analysis.
Clinical Trials Network
The NACE Clinical Trials Network is a one-stop-shop to help fast-track the start-up of national allergy trials. It is building trial-ready capacity across Australia by supporting allergy triallists and sponsors with budget, feasibility and site selection advice.
In proud partnership with
